ALLO vs LYEL
ALLO: Allogene Therapeutics is pioneering off-the-shelf, donor-derived CAR T cell therapies to provide more scalable and accessible cancer and autoimmune disease treatments. LYEL: Late-stage clinical cell therapy company engineering next-generation dual-targeting CD19/CD20 CAR T-cell therapies for blood cancers and solid tumors, with a lead program in pivotal trials and an in-house manufacturing facility.
Side-by-side fundamentals
| Metric | ALLO | LYEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.86 | $12.84 | |
| Market cap as of 2026-07-23 | $637M | $315M | |
| Net margin as of 2026-07-23 | -269835.0% | -794858.1% | ALLO higher |
| Operating margin as of 2026-07-23 | -274487.8% | -823341.9% | ALLO higher |
| ROE as of 2026-07-23 | -57.1% | -85.7% | ALLO higher |
| ROA as of 2026-07-23 | -41.6% | -66.4% | ALLO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -52.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -92.5% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 0.46 | -0.05 | |
| 1-year return as of 2026-07-22 close | +40.2% | +38.1% | ALLO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.